Verdicts genuinely change. Free email alert the moment JAZZ's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Computed from published company financials, balance sheet as of 2026-06-30. JAZZ files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 31.00% | 30.00% | Fail |
| Interest-bearing investments | 11.42% | 30.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.66% | 33.00% | Fail |
| Interest-bearing investments | 14.62% | 33.00% | Pass |
| Non-liquid assets | 77.43% | at least 20.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.66% | 33.33% | Fail |
| Cash + interest-bearing securities | 14.62% | 33.33% | Pass |
| Accounts receivable | 22.57% | 33.33% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.27% | 33.33% | Fail |
| Cash + interest-bearing securities | 14.62% | 33.33% | Pass |
| Accounts receivable | 22.57% | 50.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 40.54% | 33.00% | Fail |
| Cash + interest-bearing securities | 14.94% | 33.00% | Pass |
| Accounts receivable | 8.13% | 33.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 44.49% | 33.00% | Fail |
| Cash + interest-bearing securities | 16.40% | 49.00% | Pass |
| Accounts receivable | 8.92% | 49.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 44.49% | 33.33% | Fail |
| Cash + interest-bearing securities | 16.40% | 33.33% | Pass |
| Accounts receivable | 25.32% | 49.00% | Pass |
| Non-permissible income | 2.01% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Read from JAZZ's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $4.3B | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $4.4B | 2026-06-30 | LongTermDebtNoncurrent, LongTermDebtCurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $1.6B | 2026-06-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $11.1B | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $14.2B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $9.1B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $9.9B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $85.8M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Verdict history for JAZZ. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
ℹ️ no compliance scan has run for 6 days - this is not a reading of today
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Tweedy, Browne | Tweedy, Browne Company | $14M | 1.1% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 27.40 | BUY |
| Stochastic %K (14) | 6.77 | BUY |
| CCI (20) | -129.33 | BUY |
| Williams %R (14) | -93.23 | BUY |
| MACD (12,26,9) | -1.88 | SELL |
| ROC (10) | -10.79 | SELL |
| Momentum (10) | -25.44 | SELL |
| EMA (10) | 218.51 | SELL |
| SMA (10) | 220.09 | SELL |
| EMA (20) | 225.62 | SELL |
| SMA (20) | 228.14 | SELL |
| EMA (30) | 230.10 | SELL |
| SMA (30) | 233.07 | SELL |
| EMA (50) | 234.45 | SELL |
| SMA (50) | 239.94 | SELL |
| EMA (100) | 232.40 | SELL |
| SMA (100) | 240.46 | SELL |
| EMA (200) | 211.35 | SELL |
| SMA (200) | 214.47 | SELL |
Healthcare · Biotechnology
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Background via Yahoo Finance — informational, not part of the verdict.
Stop 220.39 Now 210.23 Target 233.46
Average — needs more confirmation before sizing up
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-13 · Asset managers net 915835 (+9220)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.